Your browser is no longer supported. Please, upgrade your browser.
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E31.60 EPS (ttm)2.53 Insider Own0.07% Shs Outstand2.53B Perf Week-1.65%
Market Cap203.97B Forward P/E11.05 EPS next Y7.24 Insider Trans-35.69% Shs Float2.52B Perf Month5.88%
Income6.43B PEG2.09 EPS next Q1.53 Inst Own74.70% Short Float0.92% Perf Quarter-1.47%
Sales47.70B P/S4.28 EPS this Y-28.00% Inst Trans-0.09% Short Ratio1.68 Perf Half Y3.15%
Book/sh14.15 P/B5.65 EPS next Y25.91% ROA7.90% Target Price92.50 Perf Year3.58%
Cash/sh- P/C- EPS next 5Y15.13% ROE23.70% 52W Range68.38 - 91.40 Perf YTD4.36%
Dividend2.76 P/FCF112.01 EPS past 5Y12.20% ROI10.80% 52W High-12.49% Beta0.45
Dividend %3.45% Quick Ratio1.10 Sales past 5Y4.00% Gross Margin68.80% 52W Low16.96% ATR1.55
Employees74000 Current Ratio1.30 Sales Q/Q4.80% Oper. Margin14.10% RSI (14)55.01 Volatility1.89% 1.83%
OptionableYes Debt/Eq0.74 EPS Q/Q55.40% Profit Margin15.10% Rel Volume1.31 Prev Close80.75
ShortableYes LT Debt/Eq0.64 EarningsFeb 03 BMO Payout91.50% Avg Volume13.75M Price79.98
Recom2.20 SMA201.28% SMA502.12% SMA2003.87% Volume18,041,128 Change-0.95%
Dec-17-21Initiated Goldman Buy $93
Dec-16-21Initiated Daiwa Securities Neutral $70
Dec-13-21Downgrade UBS Buy → Neutral $98 → $76
Dec-09-21Initiated Wells Fargo Overweight $90
Dec-07-21Downgrade Guggenheim Buy → Neutral
Nov-29-21Downgrade Citigroup Buy → Neutral $105 → $85
Nov-19-21Initiated BMO Capital Markets Market Perform $91
Nov-01-21Upgrade Argus Hold → Buy $110
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $85
Jul-27-21Resumed Truist Buy $92
May-20-21Downgrade Argus Buy → Hold
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jan-21-22 05:38PM  
03:47PM  
01:59PM  
01:47PM  
01:38PM  
12:12PM  
09:38AM  
Jan-20-22 05:45PM  
05:38PM  
04:59PM  
03:43PM  
01:51PM  
09:46AM  
08:42AM  
07:07AM  
06:45AM  
04:40AM  
Jan-19-22 05:38PM  
04:03PM  
01:38PM  
12:25PM  
09:38AM  
08:45AM  
Jan-18-22 05:00PM  
03:19PM  
01:38PM  
01:38PM  
01:38PM  
08:25AM  
08:02AM  
07:09AM  
06:55AM  
06:45AM  
Jan-17-22 08:25AM  
Jan-14-22 05:38PM  
05:38PM  
05:38PM  
10:07AM  
09:10AM  
08:20AM  
06:00AM  
Jan-13-22 11:34AM  
11:15AM  
09:38AM  
09:16AM  
09:01AM  
Jan-12-22 05:45PM  
09:38AM  
09:38AM  
Jan-11-22 03:33PM  
10:35AM  
10:32AM  
04:03AM  
Jan-10-22 05:04PM  
03:37PM  
02:52PM  
01:38PM  
12:03PM  
11:20AM  
10:07AM  
07:18AM  
06:45AM  
Jan-07-22 04:30PM  
12:09PM  
11:29AM  
08:46AM  
08:22AM  
05:00AM  
Jan-06-22 05:45PM  
09:46AM  
Jan-05-22 08:21AM  
Jan-04-22 05:00PM  
12:27PM  
11:56AM  
08:00AM  
Jan-03-22 12:25PM  
11:39AM  
06:27AM  
Jan-02-22 05:07AM  
Jan-01-22 10:30AM  
05:30AM  
Dec-31-21 01:47PM  
07:40AM  
Dec-30-21 05:45PM  
10:58AM  
09:27AM  
Dec-29-21 12:46PM  
11:59AM  
11:41AM  
Dec-28-21 03:08PM  
08:47AM  
Dec-27-21 05:51AM  
Dec-25-21 01:38PM  
Dec-24-21 12:38PM  
09:13AM  
06:45AM  
04:58AM  
Dec-23-21 06:21PM  
06:00PM  
05:38PM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CExecutive ChairNov 09Option Exercise0.00663,88101,250,676Nov 10 04:06 PM
FRAZIER KENNETH CExecutive ChairNov 09Sale82.26663,88154,611,362586,795Nov 10 04:06 PM
Litchfield CarolineEVP & CFONov 04Option Exercise0.0022,683042,449Nov 05 04:22 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthNov 04Option Exercise0.0029,7820146,712Nov 05 04:24 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthNov 04Sale90.4029,7822,692,299116,930Nov 05 04:24 PM
Litchfield CarolineEVP & CFONov 04Sale91.0018,3351,668,50324,114Nov 05 04:22 PM
Karachun Rita ASr. VP Fince-Global ControllerNov 03Option Exercise0.0025,000060,799Nov 04 04:19 PM
Karachun Rita ASr. VP Fince-Global ControllerNov 03Sale88.4525,0002,211,21535,799Nov 04 04:19 PM
Clyburn FrankEVP & Pres ? Human HealthNov 01Option Exercise0.0039,7620136,857Nov 02 06:16 PM
Gerberding Julie L.EVP, Chief Patient OfficerNov 01Option Exercise0.0096,2700135,432Nov 03 04:11 PM
Gerberding Julie L.EVP, Chief Patient OfficerNov 01Sale87.9196,2708,462,68239,162Nov 03 04:11 PM
Clyburn FrankEVP & Pres ? Human HealthNov 01Sale87.8739,7623,493,87997,095Nov 02 06:16 PM
Clyburn FrankEVP & Pres ? Human HealthOct 30Option Exercise88.052,358207,62298,257Nov 02 06:16 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise88.054,715415,15627,896Nov 02 06:11 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthOct 29Option Exercise0.00135,4050252,335Nov 02 06:12 PM
Chattopadhyay SanatExe V-P & Pres. MMDOct 29Option Exercise0.0024,6190117,764Nov 02 06:14 PM
Chattopadhyay SanatExe V-P & Pres. MMDOct 29Sale87.3224,6192,149,73193,145Nov 02 06:14 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthOct 29Sale87.56135,40511,856,265116,930Nov 02 06:12 PM
Clyburn FrankEVP & Pres ? Human HealthMay 10Option Exercise0.0019,3240113,672May 11 02:41 PM
Clyburn FrankEVP & Pres ? Human HealthMay 10Sale78.3219,3241,513,44094,348May 11 02:41 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 04Option Exercise75.9841731,6845,662May 06 05:04 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise75.981,21292,08836,215May 06 05:02 PM
Litchfield CarolineEVP & CFOMay 04Option Exercise75.981,03978,94320,230May 06 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 04Option Exercise75.9869452,7302,612May 06 04:48 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise75.981,906144,81895,287May 06 04:40 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 03Option Exercise74.5043732,5562,068May 04 05:04 PM
Litchfield CarolineEVP & CFOMay 03Option Exercise74.5075055,87519,544May 04 05:01 PM
Li Dean YExecutive VP & President, MRLMay 03Option Exercise74.5075055,87512,111May 04 04:57 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 03Option Exercise74.5041230,6945,387May 04 04:55 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise74.5087565,18835,303May 04 04:50 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 01Option Exercise74.5062246,3391,841May 04 05:04 PM
Litchfield CarolineEVP & CFOMay 01Option Exercise74.5084062,58019,082May 04 05:01 PM
Li Dean YExecutive VP & President, MRLMay 01Option Exercise74.501,03076,73511,715May 04 04:57 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 01Option Exercise74.5056041,7205,167May 04 04:55 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise74.5090167,12434,737May 04 04:50 PM